Filing summary
Evaxion A/S, a Denmark-based clinical-stage TechBio company developing AI-Immunology-powered vaccines, furnished this Form 6-K for October 2026. The report is dated October 2, 2026.
Business update
The filing announces a press release titled “Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting.” The press release is identified as Exhibit 99.1, but its contents and the underlying immune data are not included in the supplied filing text.
Financial performance and changes
The filing text provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no financial statements. It also provides no comparable-period financial information.
Outlook, risks, and contingencies
No financial guidance, detailed outlook, risk updates, contingencies, or unusual financial items are provided in the supplied text. The report states that it is incorporated by reference into specified Evaxion registration statements, subject to later filings or reports that may supersede it.
Key facts to verify
- Review Exhibit 99.1 for the actual EVX-01 immune data, presentation details, and any qualifications or limitations.
- Verify whether the SITC 2026 presentation occurred and whether additional results or updates were subsequently disclosed.
- Consult Evaxion’s financial filings for current financial performance, liquidity, and risk information, which this 6-K does not provide.